A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel

Yi Long Wu, Chang Li Wang, Mei Lin Liao, Zhong Zhen Guan, Chen Yan Gao, Shun Lu, Ming Fang Zhao, Jie Wang, Xiao Qing Liu, Jin Ji Yang, Jun Liang, Wei Min Mao, Bao Hui Han, Xu Chao Zhang, Yong Song, Ji Feng Feng, Sheng Lin Ma, Gang Wu, Cai Cun Zhou, Ke Neng ChenYing Cheng, Yong He, Chun Chen, Qun Wang, Ji Zhen Lin, Bo Zhu, Yun Peng Liu, Yi Hu, Gui Bin Qiao, Qing Zhou, Qi Bin Song, Nan Wu, Lin Wu, Cheng Huang, Xiao Long Fu, Jian Ping Xiong, Jie Hu, Cheng Ping Hu, Jian Hua Chang, Qiong Zhao, Jun Zhao, Peng Hui Zhou, Zhi Yong Ma, Yuan Chen, He Long Zhang, Fan Yang, Jian Jun Wang, Yue Yin Pan, Xue Ning Yang, Yun Fan, Zhe Liu, Wen Fan, Nong Yang, Yan Fang Guan, Hao Sun, Wen Zhao Zhong

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.

Original languageEnglish (US)
Pages (from-to)428-436
Number of pages9
JournalTranslational Lung Cancer Research
Volume7
Issue number3
DOIs
StatePublished - Jun 1 2018

Bibliographical note

Publisher Copyright:
© Translational lung cancer research.

Keywords

  • Consensus
  • Immunotherapy
  • Lung cancer

Fingerprint

Dive into the research topics of 'A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel'. Together they form a unique fingerprint.

Cite this